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Abstract 
 
 Cancer is the third leading cause of worldwide morbidity, only surpassed by 
cardiovascular and infectious diseases. Nonetheless, and despite all the efforts being made, 
humanity is as far away from real progress in fighting this pathology as it was decades ago. 
Nanotechnology has appeared as a hopeful partner in this battle, in that it has introduced new 
ways to improve the current therapies based in antineoplastic drugs. These drugs, which were 
in desperate need of improvement, tend to kill almost as much as the disease itself, through 
their aggressive systemic side effects. 
Among nanotechnology’s tools for such improvements are nanostructured lipid carriers 
(NLC) and superparamagnetic iron oxide nanoparticles (SPION). NLCs are biocompatible 
nanometric sphere-like meshes of lipids which have the ability to encapsulate drugs within its 
pores, travel through the blood stream undetected (when below 200 nanometers), slowly and 
controllably release the contained drug and deliver it to, and only to, the target location. A 
magnitude smaller, SPIONs are an agglomeration of iron oxides, usually in a sphere shape, very 
prone to modulation. They can perform a plethora of accomplishments, ranging from 
diagnostics to therapeutics and even both at the same time. 
 This thesis followed a three-pronged approach, and is thus divided as such. First and 
foremost, a paclitaxel-loaded NLC formulation was optimized through an iterative process. The 
final iteration yielded a spherical nanoparticle suspension with 117.83 nm of average diameter, 
a ζ-potential of -29.2 mV, polydispersity index of 0.113 and encapsulation efficiency higher than 
99%, which was then used as a stepping stone for the third section of this work. Secondly, a fast, 
reliable and reproducible synthesis methodology for SPIONs was designed, developed, 
optimized and characterized. The developed process was based in a microwave-assisted method 
and resulted in crystalline iron oxide nanoparticles with a near-null coercivity, in a somewhat 
broad range of diameters (5-15 nm) with a few multi-domain outliers. The possible existence of 
a thin maghemite coating was not ruled out, as there was evidence of strong interparticle dipolar 
interactions. In the last section, a paclitaxel-SPION-loaded NLC formulation was optimized 
through a Box-Behnken experimental design and characterized. The chosen formulation was 
synthesized with a ratio of solid to liquid lipid of 7, 10 mg of paclitaxel and a 15 minutes 
sonication time. It resulted in a 94.9 nm NLC with 0.165 of polydispersity index, encapsulation 
efficiency (of paclitaxel) of 81.14% and a -29.2 mV ζ-potential. SQUID and XRD measurements 
confirmed the SPIONs’ presence inside the NLCs. The formulation showed a slow and 
uncharacteristic release profile, withholding three quarters of the encapsulated paclitaxel for 
more than 68 hours, while releasing more quantity in a simulated neoplastic environment. 
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Resumo 
 
O cancro é atualmente a terceira causa de morte em todo mundo, sendo apenas 
ultrapassado por doenças cardiovasculares e infeciosas. Mesmo apesar de vários esforços 
estarem a ser feitos, a Humanidade está tão longe de atingir avanços na erradicação da doença 
como estava há décadas atrás. A nanotecnologia surge como um novo parceiro nesta batalha, 
no sentido em que possibilita melhorar as atuais terapias baseadas em fármacos 
antineoplásicos, os quais necessitam desesperadamente de aperfeiçoamento uma vez que 
tendem a matar quase tanto como a própria doença, através dos seus efeitos secundários 
agressivos e sistémicos. 
Entre as diversas nanopartículas que são hoje possível sintetizar encontram-se os 
transportadores lipídicos nanoestruturados (TLN) e as nanopartículas superparamagnéticas de 
óxido de ferro (NSOF). Os TLN são esferas lipídicas biocompatíveis, que têm a capacidade de 
encapsular fármacos, percorrer a corrente sanguínea sem serem detetados (desde que tenham 
menos de 200 nm), libertar o fármaco contido de forma lenta e controlada e entregá-lo a apenas 
um local-alvo. De um tamanho cerca de dez vezes menor, as NSOF são aglomerados de óxidos 
de ferro, comumente esféricos, facilmente modulados. Podem ter várias aplicações biomédicas 
desde diagnósticos até terapias, ou mesmo ambos simultaneamente. 
Esta tese é o resultado de uma abordagem a três vertentes, e está dividida como tal. 
Primeiramente, várias formulações de TLNs contendo paclitaxel foram desenvolvidas por forma 
a se chegar a uma formulação otimizada, através de um processo iterativo. A iteração final 
resultou numa suspensão de nanopartículas esféricas com 118 nm de diâmetro, um potencial-ζ 
de -29.2 mV, índice de polidispersão de 0.113 e uma eficiência de encapsulação maior que 99%, 
a qual foi então utilizada como base para a terceira secção deste trabalho. Em segundo lugar, 
foi desenhada, desenvolvida, otimizada e caracterizada uma metodologia para a síntese de 
NSOFs que fosse rápida, reproduzível e de confiança. O processo desenvolvido foi baseado num 
método assistido por micro-ondas e resultou em nanopartículas de óxido de ferro cristalinas 
com uma coercividade quase nula à temperatura ambiente, com um intervalo de diâmetros um 
pouco largo (5-15 nm), o que poderá indicar a existência algumas partículas com mais de um 
domínio magnético. A possível existência de uma fina camada de maghemite na superfície não 
foi desconsiderada, na medida em que se identificou uma forte interação entre partículas de 
natureza dipolar. Na última secção, uma formulação de TLN contendo paclitaxel e NSOF foi 
produzida e otimizada através de um desenho experimental do tipo Box-Behnken, tendo-se 
procedido também à sua caracterização. A formulação escolhida foi sintetizada com um rácio 
de lípido sólido para líquido de 7, 10 mg de paclitaxel e um tempo de sonicação de 15 minutos. 
O resultado final foi uma formulação com um diâmetro médio de 95 nm com 0.165 de índice de 
polidispersão, eficiência de encapsulação (de paclitaxel) de 81.1% e -29.2 mV de potencial-ζ. 
Medidas de SQUID e difração de raios X confirmaram a presença das NSOF dentro das TLNs. A 
formulação demonstrou possuir um perfil de libertação de fármaco lento e em dois regimes 
distintos, retendo três quartos do paclitaxel encapsulado durante mais de 68 horas e libertando 
maior quantidade no ambiente de simulação de cancro. 
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Chapter 1 
 
Nanotechnology in medicine 
 
  Nanotechnology represents the field of sub-micron manipulation, which allows to 
assemble and control particles of 1/80000th the size of the average human hair [1]. As the 
particle size diminishes, its physicochemical properties and environmental interactions begin to 
change, largely due to increased surface area to volume ratio. Nanoparticles can be seen as a 
bridge between the macroscopic world ruled by classical physics and the atomic world, ruled by 
quantum physics. 
Although it may seem a futuristic science, nanotechnology has emerged over 40 years 
ago, with Gerd Birrenbach’s attempt at a process he called “micelle polymerization” in 1969 [2]. 
Since then, research on nanoparticles has increased exponentially (Figure 1). 
 
 
Figure 1. Graphical representation of the number of articles published in Pubmed during the last 35 years. 
Information collected on 2015, July 7th. 
 
One of the fields most responsible for this accelerated growth is nanomedicine, the 
therapeutic and diagnostic field of nanotechnology. 
Among the therapeutic applications, the most frequently employed revolve around 
utilizing nanoparticles as delivery agents, which act as vehicles for drugs [3-5], heat releasing [6, 
7] or light emitting molecules [8] allowing them to reach specific types of cells or extracellular 
locations. These nanoparticles are engineered in such a way that they are attracted to a specific 
environment, allowing a directed treatment and, therefore, reducing the therapeutic agent’s 
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damage to bystander cells. Other less used nanotherapy techniques have also been reported, 
such as nanosponges, polymeric nanoparticles coated with a red blood cell membrane which act 
as decoys and intercept toxins in the blood stream [9] or a lens coated with carbon nanotubes 
which can convert light to tightly focused sound waves [10], among a multitude of others. 
Due to the high diversity among different nanoparticle types, they can be applied to any 
of the existing diagnostic techniques, frequently increasing their efficiency, both in output 
velocity and quality. The most commonly known application lies in Magnetic Resonance Imaging 
(MRI), where superparamagnetic iron oxides coated with a recognition molecule, such as a 
tumor-binding molecule, provide a localized contrast [11]. Another use of nanoparticles in 
diagnostic involves an encapsulation or functionalization with a fluorescent molecule, allowing 
an optical detection [12]. There are also reports of multimodal nanoparticles which comprise 
both of the previous functions [13]. In a simpler approach, semiconductor nanoparticles known 
as quantum dots have been extensively studied due to their unique physiochemical properties, 
conferred by a quantum confinement effect [14], allowing for varied applications such as 
molecule tracking [15] and fluorescence imaging [16]. 
Aside from imaging techniques, most applications can be classified as nanosensors. A 
sensor, by definition, recognizes an agent and consequently produces a signal. In 
nanodiagnostics, the detection is based on the recognition of a specific molecule or a change in 
the environment and the signal can range from an absorbance shift due to agglomeration [17], 
to a release of light [18], or a magnetic resonance change [19]. 
In the present decade, a more condensed and multifunctional strategy has surfaced, 
called theranostics, combining both diagnostic and therapy in a single agent. The purpose is to 
diagnose and treat the disease at its earliest stage, improving the likelihood of a cure. 
Nanoparticles are excellent candidates for this approach due to their high variability and 
modification possibilities [20]. All types of nanoparticles can be engineered to achieve such a 
goal, being them organic, inorganic or even a combination of both [21-24]. 
A somewhat recent review (2013) on the current state of nanomedicine showed that 
most approved and investigated products on this field are categorized by the U.S. Food and Drug 
Administration as drug nanocarriers, more than 80% of which are intended for cancer treatment 
[25]. It is therefore obvious the existence of a keen oncological interest by today’s population of 
“nanoresearchers”. 
 
Nanomedicine in Cancer 
 
 The World Health Organization attributed 8.2 million worldwide deaths to cancer in the 
year of 2012, approximately 13% of all reported deaths, with a 70% estimated increase of cancer 
cases in the next two decades [26]. One of the main reasons for such high numbers is the lack 
of efficient treatment. Current antineoplastic agents have poor selectivity, which, in practice, 
corresponds to a dose-limiting toxicity and systemic action, i.e. either the drug is in a too low 
concentration, resulting in death by cancer progression, or too high, resulting in the death of 
healthy cells by drug toxicity. In some cases, the drug concentration could actually be the same 
in both situations. Alas, the need for a targeted delivery of said drugs is of paramount 
importance to overcome current oncological treatments’ limitations and allow the patient to 
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outlast its illness, to which nanotechnology responded. Nanoparticles have the potential to 
increase a drug’s in vivo stability, extend its blood circulation time, control its release and alter 
its biodistribution, through either passive or active targeting, essentially allowing for a controlled 
modulation of the drug’s pharmacokinetic and pharmacodynamics profiles. 
 In Table 1 are summarized the approved nanoparticles for cancer therapy, evidencing 
the focus on liposome-type formulations. 
 
Table 1. Marketed and approved nanoparticles for cancer therapy applications. 
Product 
(Company) 
Vehicle Drug Indication Approval Ref. 
DaunoXome® 
(Galen) 
Liposome 
Daunorubici
n 
Kaposi’s 
sarcoma 
1996 [27] 
DepoCyt® 
(Pacira) 
Liposome Cytarabine 
Neoplastic 
meningitis 
1999 [28] 
Doxil® 
Caelyx® 
(Johnson & 
Johnson) 
Liposome Doxorubicin 
Kaposi’s 
sarcoma 
Ovarian and 
breast cancer 
Multiple 
myeloma 
1995, 1999, 
2003 and 
2007 
[29] 
Genexol-PM® 
(Samyang 
Biopharm) 
PEG-PLA 
polymeric 
micelle 
Paclitaxel 
Breast, lung 
and ovarian 
cancer 
2007 [30] 
Lipo-Dox® 
(Taiwan Liposome) 
Liposome Doxorubicin 
Kaposi’s 
sarcoma 
Breast and 
ovarian cancer 
1998 [31] 
Marqibo® 
(Talon) 
Liposome Vincristine 
Acute 
lymphoid 
leukemia 
2012 [32] 
Mepact® 
(Takeda) 
Liposome Mifarmutide Osteosarcoma 2009 [33] 
Myocet® 
(Cephalon) 
Liposome Doxorubicin 
Breast cancer 
(in conjunction 
with 
cyclophospha
mide) 
2000 [34] 
NanoTherm® 
(Magforce 
Nanotechnologies) 
Iron oxide 
nanoparticle 
None1 Glioblastoma 2010 [35] 
1Intended purpose is thermal ablation instead of drug vehicularization. 
  
 The United States clinical trials registry contains, as of September of 2015, 1620 
registries under the keyword “liposome” and 206 under “nanoparticle”, which, when compared 
to the previously listed nine formulations, indicate a growing trend in nanotechnological 
approaches to cancer therapies. 
4 
 
 
Objectives and reasoning 
 
 The elaborated thesis encompassed several objectives, which can be grouped into three 
different sections. 
 Current pharmaceutical treatments for neoplasms are mostly based on extremely 
hydrophobic drugs. Such compounds have stability issues in the blood stream and require third-
party molecules, known as excipients, to function. Additionally, they have lack of selectivity, 
affecting both healthy and diseased tissue alike. In this sense, the first objective was to design 
and develop a Paclitaxel-loaded nanostructured lipid carrier (NLC) formulation. Paclitaxel was 
chosen due to its degree of hydrophilicity, which is one of the highest known to drugs, 
representing the ideal experimental subject. The lipid matrix of NLCs confers the perfect 
environment for Paclitaxel’s presence, while their surfactant-stabilized surface would 
hypothetically permit a very high and long-term stability in aqueous media. Additionally, and 
perhaps most importantly, they may confer occlusion and bar the Paclitaxel’s destructive 
potential until it reaches its target destination – tumoral tissue. 
 Magnetic nanoparticles have been establishing an ever-increasing ground in 
nanomedicine. Albeit more present in diagnostics, they have a wide range of therapeutic 
capabilities. However, their current commercialization is deficient, largely due to morose and 
inefficient largescale synthesis methodologies. Such leads to the second objective of this thesis, 
the development, optimization and characterization of superparamagnetic iron oxide 
nanoparticles (SPIONS). SPIONs were chosen as focus due to a plethora of reasons. First and 
foremost, they are comprised of solely iron, a material widely known as biocompatible (in 
sensible quantities). Secondly, SPIONs are abundant in the scientific literature, with well-
described and extensive characterizations, and are already clinically approved and marketed 
(such as Feridex [36], Feraheme [37] and MION-46L [38]). Thirdly, the reagents needed for their 
synthesis are cheap and easily acquired and a functioning protocol for their synthesis would be 
a useful asset to the laboratory. Furthermore, their superparamagnetic behavior confers 
hyperthermic capabilities - an increase of energy, dissipated as heat, caused by an applied 
alternated magnetic field. 
 The thesis’s third and ultimate objective consisted on the innovative combination of 
both previous sections with the intention of creating a synergistic behavior. The synthesis and 
characterization of this novel formulation, the Paclitaxel-SPION-loaded NLCs, could lead into 
insights about unexplored reaches of nanotherapeutics and, ideally, result in a massive advance 
of the drug’s effectiveness. 
  
5 
 
 
Chapter 2 
 
Lipid nanoparticles 
 
Introduction 
 Lipid nanoparticles are defined as sub-micron sphere-like arrangements of lipid-based 
molecules held together by a surfactant. Due to its unique composition, these particles usually 
attain GRAS (generally recognized as safe) status, since its components are biomolecules 
commonly found in the human body or known to be biocompatible [39]. 
Currently, this classification encompasses many different types of nanoparticles 
depending on composition and synthesis method, albeit only two are mainly developed and 
studied, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). 
First developed during the early 1990s [40], SLNs are composed of 0.1-30% (w/w) solid 
lipid dispersed in an aqueous solution of 0.5-5% (w/w) surfactant [41]. These nanoparticles tend 
to exhibit a good physicochemical stability, protection and controlled release of the 
encapsulated drug, low cytotoxicity, organic solvent free synthesis and an ease of scale-up [39]. 
However, due to their high crystallinity and ordered matrix (Figure 2.A), they can suffer from 
low encapsulation efficiency and a possible drug expulsion during storage [42], depending on 
the structure of the drug. 
To circumvent such limitations, a second generation of lipid nanoparticles was 
developed. The addition of a liquid lipid to the formulation allows a less ordered lipid matrix 
and, consequently, more room for the active compound (Figure 2.B) [43]. 
 
 
 
Figure 2. Lipid matrix representation of solid lipid nanoparticles (A) and nanostructured lipid carriers (B). 
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These types of nanoparticles have shown great potential in cancer treatment research. 
Albeit none is already approved or in ongoing clinical trials, numerous in vitro and animal models 
assays have been conducted successfully and reported in the literature. A very succinct fraction 
of which is shown in Table 2. 
 
Table 2. Small sample of lipidic nanoparticles’ research in cancer therapy. 
Vehicle 
Surface 
modification 
Drug Cancer type Reference 
NLC Pegylation 10-hydroxycamptothecin 
Lung 
adenocarcinoma 
[44] 
NLC - Celecoxib 
Non-small cell lung 
cancer 
[45, 46] 
NLC - Tamoxifen Breast cancer [47] 
NLC 
Layer-by-layer 
polyelectrolyte 
and pegylation 
Doxorubicin 
Lung 
adenocarcinoma 
and breast cancer 
[48] 
NLC - Zerumbone 
Acute 
lymphoblastic 
leukemia 
[49] 
NLC Hyaluronic acid Baicalein and doxorubicin Breast cancer [50] 
NLC - Thymoquinone 
Breast and 
cervical cancer 
[51] 
NLC Hyaluronic acid 
5-fluorouracil and 
cisplatin 
Gastric cancer [52] 
NLC - Curcumin Brain cancer [53] 
NLC Enoxolone Curcumin Liver cancer [54] 
NLC 
Folate-poly(PEG-
cyanoacrylate-co-
cholesteryl 
cyanoacrylate) 
copolymer 
Docetaxel 
Unspecified mouse 
tumor 
[55] 
NLC Hyaluronic acid Paclitaxel 
Melanoma and 
colon carcinoma 
[56] 
SLN - Docetaxel Breast cancer [57] 
SLN - Resveratrol Brain cancer [58] 
SLN - Etoposide 
Melanoma 
metastasis in lung 
[59] 
SLN Transferrin 
Doxorubicin and 
enhanced green 
fluorescence protein 
plasmid 
Lung 
adenocarcinoma 
[60] 
SLN Pegylated peptide Paclitaxel 
Fibrosarcoma, lung 
carcinoma 
[61] 
SLN - Butyrate 
Promyelocytic 
leukemia 
[62] 
SLN - Camptothecin Brain cancer [63] 
SLN - 
Docetaxel and conjugate 
of folic acid and oxidized 
Liver cancer [64] 
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single-walled carbon 
nanotubes 
SLN Hyaluronic acid Vorinostat 
Tongue squamous 
cell carcinoma and 
lung 
adenocarcinoma 
[65] 
SLN Folic acid 
Docetaxel and 
ketoconazole 
Brain 
endothelioma 
[66] 
 
 
Paclitaxel 
Paclitaxel, as well as the other taxanes, acts by decreasing the critical concentration of 
tubulin needed for microtubule assembly, promoting its formation and hindering its detachment 
[67]. This destabilization of functional microtubule dynamics leads to the impossibility of some 
essential cell processes, such as movement, chromosome segregation and cell division, 
ultimately resulting in the cell’s unrest and self-induced apoptosis [68]. 
Along with his structural cousin docetaxel, paclitaxel (Figure 3) is the highlight of the 
taxane family. His tetracyclic heptadecane skeleton confers a staggeringly low hydrophilicity, 
which was reported to be as low as 0.357 µg/mL [69]. In fact, its behavior in aqueous media lead 
to the addition of third party molecules, as excipient or binder, as the only method to stabilize 
this taxoid, with the examples of the two most important marketed forms of paclitaxel, Taxol®, 
where it is dissolved in a 50/50 (w/w) solution of polyoxyethylated castor oil (Cremophor EL - 
CrEl) and dehydrated ethanol [70], and Abraxane®, in which the taxoid molecule is conjugated 
to albumin (nab-paclitaxel) [71]. 
 
 
Figure 3. Paclitaxel structural and chemical configuration. 
  
The first of the previously enunciated formulations is largely accompanied by undesired 
pharmacokinetic profiles, due to paclitaxel’s extensive binding to serum albumin, and 
consequent inactivity [72], broad tissue distribution, albeit incapable of passing the blood-brain 
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barrier [73], and a low half-life of 2.9 ±0.3 hours [74]. Additionally, the excipient CrEl only 
worsens such effects [75]. 
The second formulation, on the other hand, demonstrates an increased treatment 
response and slower disease progression with a simultaneous significantly decreased systemic 
toxicity [76]. It requires, however, recombinant albumin for its synthesis, relating into a much 
higher cost and, consequently, turning the better antitumor efficacy relatively marginal. 
Nano-sized delivery systems have therefore attracted a heightened attention in the 
current millennium as a strategy to overcome the limitations of simpler paclitaxel therapy 
approaches. 
Firstly, a nanoparticle system would provide physical and chemical protection for the 
very water insoluble and metabolic degradation-prone molecule through its entrapment, 
allowing a higher injectable concentration and completely removing the excipient’s presence 
and toxicity. Secondly, nano-based formulations could improve the paclitaxel’s 
pharmacokinetics through drug occlusion (lack of epitopes recognizable by the immune system), 
a controlled release profile and possible surface modification (such as pegylation). Thirdly, a 
nanoparticle can take advantage of the Enhanced Permeation and Retention effect (EPR), a 
passive targeting approach where small particle (less than circa 400 nanometers) accumulate in 
cancer tissue through defective neo-angiogenic blood vessels [77], or it can be modulated into 
partaking an active targeting, with molecules such as folic acid, transferrin and hyaluronic acid. 
Both the previous targeting methods result in an improved biodistribution of the anticancer 
agent. Finally, the nano-sized systems have a limitless potential in versatility and functionality 
modulation. They allow for co-delivery of multiple agents, being it synergistic drugs, a 
theranostics combination or anything else. They can also be positively, neutral or negatively 
charged, depending on which suits the synthesizer needs. Environment responses are also 
possible, such as a pH-, heat-, light- or magnetically-responsive structural change. 
A myriad lipid-based nanoparticles have already been reported to effectively deliver 
paclitaxel. 
Liposomal formulations encapsulating paclitaxel have showed a steep decrease in side 
effects while maintaining a similar to slightly higher antitumor activity when compared to Taxol® 
[78-80] and even managed to show a significant tumor inhibition in a Taxol®-resistant murine 
model [81]. Liposomes, however, contain an aqueous core, leading to disappointing 
encapsulation efficiencies of hydrophobic drugs such as paclitaxel. 
On the other hand, SLNs are composed of a solely lipid matrix, more easily 
accommodating such drugs, leading to higher encapsulation efficiencies and slower release 
profiles, as has been reported by Cavalli et al (0.1% release in PBS during 2 hours [82]), Yegin et 
al (12.5-16.5% within 14 days [83]) and Lee at al (10% in 24 hours [84]). The in vitro cellular 
uptake and cytotoxicity has also been shown to be influenced by the lipid matrix composition 
and surfactant [85-87], which is most likely explained by specific affinities of cell membranes to 
different lipids. Dong et al presented a clever use of surfactant (Brij 78) which provoked a 
temporary reduction in intracellular ATP levels partially inhibiting the energy-dependent P-gp 
efflux (a drug efflux mechanism that some tumors employ) in a P-gp overexpressing human 
ovarian carcinoma cell line, effectively bypassing its drug resistance. An unexpected find 
revealed the propensity of SLNs to deliver paclitaxel to the brain, passing through the blood-
brain barrier without an active mediator [88]. 
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As stated in the previous chapter, the SLNs’ matrix confers potential disadvantage 
issues, which NLCs were developed to resolve. However, being the most recent addition to the 
lipid-based nanoparticle family, the reports of successful paclitaxel-loaded NLC formulations are 
staggeringly scarce. As of the time of writing, the author could only locate five divulged papers 
on the subject [56, 89-92], three written by the same authors. Yang et al developed started with 
the development of hyaluronic acid-coated NLC formulation and reported its higher 
effectiveness in murine melanoma, mouse colon and human colon cancer cell lines, and in vivo 
in Kumming mice when compared to Taxol® [56]. They later went on to disregard the hyaluronic 
acid and include a surface modification of a photo-responsive cell-penetrating peptide and again 
reported a higher antitumor efficacy against non-functionalized NLCs and Taxol®, this time in 
human fibrosarcoma cells [89]. More recently, in 2015, he included another molecule to the 
formulation’s surface functionalization, a NGR peptide (Asn-Gly-Arg), reporting an even greater 
antitumoral efficacy in comparison to all earlier formulations, in both the previously studied cell 
line and a new human breast adenocarcinoma one [90]. The other two reports were developed 
for pulmonary delivery. Kaur et al underwent a Box-Behnken design optimization of all 
conceivable parameters and evaluated the optimal formulation against a plain drug solution, 
reporting a circa 3-fold increase in paclitaxel lung concentration [91]. Lastly, Taratula et al 
developed a NLC co-delivery system containing paclitaxel (or doxorubicin) and siRNA for the 
suppression of proteins responsible for drug resistance in cancers, with the addition of a 
synthetic hormone analog as a targeting moiety specific to lung cancer cells. His data evidenced 
a much higher effectiveness with the targeted paclitaxel-NLC than with placebo and free 
paclitaxel with an almost complete cancer regression when siRNA is co-encapsulated [92]. 
Hence, it is obvious the utmost importance to explore deeper into the vastly untapped 
potential of paclitaxel-loaded nanostructured lipid carriers. 
 
NLC synthesis 
To date, various techniques have been reported for the synthesis of lipid nanoparticles. 
One of such is high pressure homogenization, which can be further divided into hot [93] 
and cold [94] variants. In both, the active compound is dissolved in the previously melted lipid 
blend. The variants then differ in the addition of a hot or cold aqueous surfactant solution, 
respectively, and the temperature at which the microemulsifying step is conducted. These 
techniques offer some advantages, such as a narrow particle size distribution with a low content 
of microparticles, avoidance of organic solvents and a great ease of scale-up accompanied by a 
frequent availability of the equipment required in industrial laboratories [95]. 
Another methodology is o/w microemulsion, which is based on the dispersion of warm 
microemulsions in cold water under stirring, leading to a nanoprecipitate [96]. Unfortunately, in 
this method a high concentration of surfactants and co-surfactants are used and results in very 
small yields. Variations of the previous method, also based on the breaking of an o/w 
microemulsion into a nanoemulsion, rely on solvent evaporation, diffusion or injection molding. 
In the emulsification-evaporation process, the lipid is first dissolved in an organic solvent and a 
microemulsion is created through the addition of an aqueous phase containing a surfactant. 
Subsequently, the solvent is left to evaporate under normal or reduced pressure while at room 
temperature, resulting in a nanoprecipitate in the aqueous medium, with the benefit of avoiding 
possible heating-related issues [97]. The emulsification-diffusion methodology, on the other 
hand, was developed for lipids which could not be dissolved in the organic solvent under 
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ambient conditions. Consequently, both the lipids and the solvent are mixed while in a heated 
water bath for the dissolution to occur. An addition of water to the organic solution results in 
coacervation and formation of lipid nanoparticles, which are then collected by 
ultracentrifugation, solvent evaporation or cross-flow filtration [98]. The third method, injection 
molding, represents a faster, mechanically-aided solvent-diffusion technique, as lipids dissolved 
in a water miscible organic solvent are rapidly injected into an aqueous phase, resulting in 
coacervation and a nanoparticle dispersion. This process has the specific advantage of a 
simultaneous efficiency, tight conditional control (by parameter variation) and simple 
mechanical implementation (the most technically complex apparatus is a syringe) [99]. 
However, all 3 of these methods sin on the utilization of organic solvents and their 
accompanying toxicological and environmental hazards. Additionally, the first two present a 
fairly dilute nanoparticle suspension, largely due to the limited solubility of lipids in the solvents. 
A clever way to ensure a higher hydrophilic drug encapsulation efficiency resulted from 
the double emulsion technique. This method stands on the drug’s dissolution and entrapment 
in the internal aqueous phase of a w/o/w emulsion, along with a stabilizer, in order to prevent 
its partitioning to the outer phases during solvent evaporation. It is initiated as a warm w/o 
microemulsion, resulting from the addition of drug, water, stabilizer and melted lipids, which is 
then dispersed into another stabilizer-containing water solution forming a w/o/w [100]. The 
nanoparticles are ultimately collected through diafiltration. This technique yields good results 
with sensitive drugs, such as peptides and nucleic acids, if an organic solvent is utilized for the 
lipid’s dissolution instead of heat, although with the advent of common organic solvent 
disadvantages [101]. Another disadvantage is the relatively small aqueous inner compartment 
compared to the whole lipid matrix, resulting in, likewise, comparatively inferior encapsulation 
efficiencies. 
NLCs can also be synthesized by ultrasonication in conjunction with [102], or absence of  
[103, 104], high shear homogenization. In this technique, lipids, surfactant and drug are all mixed 
together in a water bath at a high enough temperature to melt the lipids. Water, at the same 
temperature, is then added to the previous mixture, resulting in an emulsion, which is, 
optionally, subjected to high shear forces through high speed stirring, such as with a rotor-stator 
homogenizer, to form a microemulsion. Lastly, the particles undergo high strain during 
ultrasonication, due to cavitations caused by sonic waves, extremely elevated and localized 
temperature and pressure occurrences by collapsing bubbles, resulting in a suspension of 
nanoparticles. The greatest advantages of this methodology are the complete absence of 
organic solvents, ease and velocity of process and commonly available equipment. However, 
there is a possible metal contamination from particles released by the sonicator’s tip, commonly 
associated with its usage, being it recently acquired or age-old. The other, much more frequent 
disadvantage is the broad particle size distribution, largely resolved by a higher surfactant 
concentration (which could, in turn, lead to toxicity issues) or the absence of high speed stirring. 
Additionally, it is possible to employ this technique in a standalone high sheer homogenization 
version [105], although unadvisable due to the stated broad distribution problem. 
The standalone ultrasonication method, was the chosen technique for this work, due to 
the extensive experience in its employment, good advantage to disadvantage ratio and the 
presence of a sonicator in the laboratory. 
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Reagents and equipment 
 The chosen lipid blend comprise  Gelucire® 43/01, Compritol® 888 ATO and Miglyol® 812 
while the chosen surfactant Tween® 80. 
 Gelucires are blends of mono-, di- and triglycerides with polyethylene glycol esters of 
fatty acids marketed by Gattefossé. In particular, Gelucire® 43/01 has a melting point of 43oC 
and HLB of 1. Compritol® 888 ATO, also marketed by Gattefossé, is a blend of different esters of 
behenic acid with glycerol. It has a melting point of 70°C and HLB of 1. On the other hand, 
Miglyol® 812 is marketed by Acofarma Distribuición and comprised of a mixture of caprylic and 
capric triglycerides. It has a melting point lower than 0°C and HLB of 15.36. Tween® 80, the 
surfactant, is the trademark name for Polyethylene glycol sorbitan monooleate marketed under 
Sigma-Aldrich, a biocompatible and amphoteric molecule. 
 The described lipid combination was chosen taking into account the need of having a 
formulation which melted when the temperature arose higher than 40-45oC. Additionally, 
paclitaxel’s solubility was taken into account by conducting lipophilicity tests. Compritol® 888 
ATO was also added to counterbalance the melting point of Miglyol® 812 and to introduce an 
even higher degree of disorder to the nanoparticle’s matrix, thereby increasing the drug load. 
 Paclitaxel was bought from LC Laboratories and utilized without further treatment. 
The probe-sonicator utilized was a VCX130 from Sonics & Materials, Inc. (130 W of 
maximum potency) and the double-deionized water was filtered through a nanopore membrane 
(conductivity lesser than 0.1 μS.cm-1). 
 
Ultrasonication technique 
 The methodology herein described was an adaptation of the protocols followed by the 
research group and is summarized in Figure 4. 
 
 
Figure 4. Representative diagram of the NLC synthesis process by a standalone ultrasonication technique. From left 
to right: addition of water to melted lipid, surfactant and drug, sonication and final product. 
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The optimized formulation was synthesized as followed. 70% (w/w) of Gelucire® 43/01, 
6% (w/w) of Compritol® 888 ATO, 10% (w/w) of Miglyol® 812, 12% (w/w) of Tween® 80 and 2% 
(w/w) of Paclitaxel were weighted and stored in a glass tube. The tube was then placed in a 
water bath at 75oC until all lipids had melted and magnetically stirred to suspend the drug. 
Afterwards, 16 mL of double distilled water, pre-heated at 75oC were added, obtaining an 
opaque, white suspension, which was placed under the probe-sonicator at 104 W of potency 
during 10 minutes. The resulting white nanoemulsion was stored in a sealed glass vial and left 
to cool at room temperature. 
 
Encapsulation efficiency assessment 
 Encapsulation, or entrapment, efficiency is defined as the percentage of encapsulated 
drug relative to the total added amount [106]. Hence, in this work, the percentage was 
determined by measuring the unentrapped paclitaxel’s amount and calculating its inverse 
relativized to the absolute quantity initially added, as per the equation: 
 %𝐸𝐸 =
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑎𝑐𝑙𝑖𝑡𝑎𝑥𝑒𝑙−𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑓𝑟𝑒𝑒 𝑝𝑎𝑐𝑙𝑖𝑡𝑎𝑥𝑒𝑙
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑎𝑐𝑙𝑖𝑡𝑎𝑥𝑒𝑙
∗ 100 (2.1) 
 The study of the in vitro behavior of Paclitaxel in an aqueous medium is a gargantuan 
task, due to the difficulty of maintaining a good sink condition derived from Paclitaxel’s 
infinitesimal water solubility. In order to overcome such difficulty, a hydrotropic agent was used, 
sodium salicylate, which has already been reported to increase Paclitaxel’s solubility by 100 
times at 1 M concentration [107]. 
 The sodium salicylate was purchased from Merck and utilized without further 
modification.  
Initially, the assessment of particle stability in sodium salicylate had to be made. 
Therefore, size and ζ-potential measures and aggregates determination were conducted under 
different concentrations of the hydrotrope. The Paclitaxel-loaded NLCs presented as stable at 
concentrations as high as 0.5 M, upon which they started to deform and aggregate. 
 For the unentrapped paclitaxel assessment, a formulation sample was diluted in double 
deionized water with sodium salicylate at 0.5 M concentration, at a 1:100 ratio, and placed 
inside an Amicon® Ultra-4 Centrifugal Filter Device (Millipore). Centrifugation was then 
performed using a Jouan BR4i multifunction centrifuge (Thermo Electron) with a fixed 23o-angle 
rotor at 3500 rotations per minute for 30 minutes (Figure 5). Afterwards, the supernatant, which 
contained the unentrapped paclitaxel, was collected and the concentration was quantified 
through a V-660 spectrophotometer (Jasco) at 200-400 nm. 
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Figure 5. Centrifugation step of the encapsulation efficiency assessment methodology. 
 
Characterization techniques 
Cryo-scanning electron microscopy (Cryo-SEM) 
 The SEM technique relies on the emission of an electron beam from a tungsten filament, 
which, when it contacts with a sample’s surface, provokes the ejection of low-energy secondary 
electrons by inelastic scattering, high-energy backscattered electrons by elastic scattering and 
x-ray radiation. These signals can be measured by different detectors to gather information 
about the topology and chemical composition of the sample [108]. 
 SEMs operate under high vacuum, which tends to cause the nanoparticle’s deformation, 
or even rupture, since NLCs are known to be very labile. Additionally, the ones synthesized 
during this work have a melting point of little higher than 40oC, increasing their fluidity to even 
higher proportions. To circumvent such limitations, a cryogenic variant of sample preparation 
was utilized, where the sample is previously fixed with liquid nitrogen. 
 The images obtained for this work were measured by a FEI Quanta 400FEG SEM system 
and conducted in Centro de Materiais da Universidade do Porto (CEMUP). 
 
Dynamic and Electrophoretic Light Scattering (DLS and ELS) 
 When a light source emits radiation upon small particles, the light scatters, a 
phenomena known as Rayleigh scattering. If the source is a laser (monochromatic and coherent) 
the scattering suffers an intensity fluctuation due to the particles’ Brownian motion. The 
information acquired, post autocorrelation, from this fluctuation permits the calculation of a 
particle’s translational diffusion coefficient, which can be equated into the particle’s 
hydrodynamic radius by the Stokes-Einstein-Sutherland equation: 
 𝑟ℎ =
𝑘𝐵𝑇
6𝜋𝜂𝐷
 (2.2) 
where rh is the hydrodynamic radius, kb the Boltzmann’s constant, T the absolute temperature, 
η the solution’s viscosity and D the diffusion coefficient [109]. The hydrodynamic radius of a 
particle represents the radius of a hard sphere that diffuses at the same rate as the particle, 
which can be considered the same when applied to nanostructured lipid carriers since they are 
quasi-spheres. 
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 Electrophoretic light scattering is a variant of the dynamic technique, where, instead of 
Brownian motion, an oscillating electric field is responsible for the particles’ mobility. Through 
the data obtained, the particles’ electrophoretic mobility is determined, which can then be 
related to their ζ-potential by a variety of models, the most common being Smoluchowski’s: 
 𝜈𝐸 = 4𝜋𝜀0𝜀𝑟
𝜁
6𝜋𝜂
(1 + 𝑘𝑟) (2.3) 
where νE represents the electrophoretic mobility, εr and ε0the relative dielectric constant and 
electrical permittivity of vacuum respectively, r the particles’ radius and k the Debye-Hückel 
parameter [110]. The ζ-potential represents the nanoparticle’s electric potential at the slipping 
plane, the boundary beyond which ions in solution do not suffer any interaction by the particle’s 
mobility. This potential is closely related with the particle’s stability in suspension.  
 For the purpose of this work, both size and ζ-potential measures were performed with 
a NanoBrook 90Plus PALS Particle Size Analyzer from Brookhaven Instruments Corporation, with 
the addition of a BI-ZEL electrode for ELS. 
 
Results and discussion 
The synthesis methodology described above corresponds to the optimized NLC 
formulation, in respect to size, ζ-potential, polydispersity index and encapsulation efficiency. 
This optimization was conducted following an iterative approach, which is based on a create-
assess-learn-recreate routine, applying changes in lipid ratios, water and surfactant content and 
sonication time and potency as needed. 
In Table 3 are depicted the physicochemical characteristics of a small fraction of the 
synthesized formulations. This table was kept summarized due to the sheer amount of NLCs 
synthesized. 
 
Table 3. Physicochemical parameters of some of the synthesized NLC formulations during the optimization process. 
Formulation # Size (nm) Polydispersity index (adimensional) ζ-potential (mV) 
8 369.8 0.187 -31.52 
11 281.3 0.137 -29.62 
14 498.2 0.302 -28.81 
16 248.5 0.147 - 
20 308.4 0.249 - 
23 295.1 0.263 - 
27 474.8 0.240 -30.15 
29 290.5 114.9 - 
32 347.4 0.164 - 
35 368.3 0.145 - 
37 229.1 0.109 - 
38 210.9 0.160 - 
39 235.0 0.155 - 
40 239.2 0.173 - 
41 245.5 0.113 -29.23 
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The ζ-potential started as being measured at every new formulation. However, when 
noticing it would only change within the electrode’s sensibility range, it started to be measured 
at more spacious intervals. In a similar note, the relationship between encapsulation efficiency 
and the synthesis’s parameters was not thoroughly examined, as this section was only meant to 
be used as a starting point in size, polydispersity and ζ-potential for the later experimental work 
and it was expected for it to drastically diverge when the magnetic nanoparticles were 
introduced, and therefore only on the last formulation was it assessed. 
The optimized formulation presented a mean hydrodynamic diameter of 245.5 ±0.1 nm, 
with 99.96% of all nanoparticles below 117.83 nm, and polydispersity index of 0.113 ±0.008, 
both measured by DLS. Besides being greatly monodisperse, these results are in agreement with 
the initial objective of having a nanoparticle smaller than 200 nm to avoid capture by the 
Mononuclear Phagocyte System [111] and to take advantage of the Enhanced Permeation and 
Retention effect (EPR) [77]. The ζ-potential of -29.2 ±0.5 mV, measured by ELS, is considered 
optimal, since it leads to a lack of aggregation and low cytotoxicity [112]. The entrapment 
efficiency of the optimized formulation was found to be above 99%. It was not possible to 
ascertain a specific percentage due to the supernatant’s absorbance being lower than the 
spectrophotometer’s sensitivity. This result is slightly higher than the efficiencies reported by 
other authors, which ranged from 90% to 95% [56, 89-91]. 
Cryo-SEM imaging was utilized instead of the conventional TEM and SEM. Since the 
nanoparticles were engineered with the purpose of melting at around 40oC, they have a high 
fluidity at room temperature. Due to this plasticity, the vacuum required for TEM/SEM imaging 
distorted the nanoparticles, leading to the necessity of freezing them prior to observations. The 
images collected (Figure 6) were in agreement with the results obtained by the light scattering 
techniques. Additionally, no noticeable change in diameter resulted from Paclitaxel’s 
encapsulation. 
 
 
Figure 6. Cryo-SEM images of the placebo (A) and Paclitaxel-loaded (B) nanostructured lipid carrier formulation.  
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Chapter 3 
 
Magnetic nanoparticles 
 
Introduction 
Magnetism occurs from the motion of electrically charged particles, such as protons, 
electrons and neutrons (although neutrons are neutral, they consist of smaller electrically 
charged particles) [113]. Hence, since every material in nature is composed by them, all have an 
intrinsic property called magnetization, M, which is regarded as the vector sum of all its 
individual constituents’ magnetic moments. When a material is placed in contact with an 
external magnetic field, H, its magnetization creates a larger induced magnetic field, B, in a 
phenomena called magnetic induction, where µ0 represents the permeability of free space [114, 
115]: 
 𝑩 = µ𝟎(𝑴 + 𝑯) (3.1) 
 Since the magnetic properties of a material should be measured as a direct 
magnetization response dependent on an applied magnetic field, the magnetic materials 
categorization relies on the ratio between those two physical entities, which is called the 
magnetic susceptibility, χ [114, 115]: 
 𝛘 = 𝐌/𝐇, −1 < χ < +∞ (3.2) 
There are two categories under which magnetic materials can be classified depending 
on their magnetic susceptibility: paramagnetism, when it is positive, and diamagnetism, when it 
is negative. Diamagnetism refers to the case where the magnetization in a material physically 
opposes the applied field H, consequently reducing it. Lenz’s law states that “If an induced 
current flows, its direction is always such that it will oppose the change which produced it”. Such 
statement means that, under an applied magnetic field, the electrons in atomic orbitals will 
slightly adjust their orbits with the intent of creating current loops that oppose said field [116]. 
The result is that every material has an innate diamagnetic property, albeit very small in most 
cases [117]. Nonetheless, even though all materials present diamagnetic properties, in some it 
is negligible compared to a positive magnetic susceptibility created by the magnetic moments 
of unpaired electrons when they align with an applied field, a property known as paramagnetism 
[118]. 
A less broad classification method relies on the relative ordering of the magnetic 
moments contained in a material (Figure 7). The absence of diamagnetic properties is due to the 
inexistence of magnetic moments in such substances. In paramagnetic materials, each magnetic 
moment is randomly oriented due to thermal energy, as shown in Figure 7.A. However, if the 
temperature decreases, the magnetic interaction between the magnetic moments 
predominates over the thermal energy’s influence, causing a characteristic ordered state. In 
ferromagnetic materials (Figure 7.B), this ordering is parallel and happens below the Curie-
Weiss temperature, while for antiferromagnetic materials (Figure 7.C) the ordering is 
antiparallel and occurs below the Néel temperature. These critical transition temperatures are 
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properties individual to each material’s chemistry and magnetic characteristics. Lastly, there is 
a variant of antiferromagnetism where each interacting pair of magnetic moments have 
different magnitudes (Figure 7.D) [114, 115, 117, 118]. 
 
 
  
 There is one other magnetic state which these classifications fail to encompass, since it 
cannot be described by an ordering of domains. When a magnetic material is very small, ranging 
from atomic scale to a couple dozens of nanometers depending on the material (as example, 
circa 20 nanometers for magnetite [119]), it starts behaving as a single giant magnetic domain. 
In this state, materials behave similarly to paramagnets, by avoiding any reminiscent 
magnetization after the magnetic field removal, but have a much higher susceptibility [120]. Like 
the previously described magnetic states, superparamagnetic materials also have a critical 
transition temperature specific to each material’s composition. However, since they are a single 
magnetic domain particle, below this temperature they are in a blocked state, ignoring any 
external field, hence it is known as blocking temperature [121]. 
The easiest way to distinguish between the different magnetic states is to analyze a 
material’s M-H curve (Figure 8). If we apply an increasing magnetic field on a ferromagnet and 
subsequently decrease it, the magnetization does not follow the initial magnetization curve. This 
irreversibility is called hysteresis, and it occurs because the magnetic susceptibility is not a scalar, 
but a vector. At high applied fields, the magnetization approaches saturation magnetization, 
(Msat), where every magnetic domain is aligned, and, when such field is removed, remanent 
magnetization (Mr), where some of the domains do not return to the original state. The sole 
manner to return these domains to their basal state is to apply a negative field, having a specific 
magnitude denominated coercive field (Hc) where the magnetization returns to zero. The 
hysteresis curve follows a symmetric pattern if the applied field varies from positive to negative 
values. Materials with a coercive field greater than 1000 A.m-1 (circa 12 Oe) are called hard 
magnets, whereas soft magnetic materials are those with below that value [122]. In biological 
Figure 7. Possible orderings of magnetic moments: (A) paramagnetic; (B) ferromagnetic; (C) antiferromagnetic; and 
(D) ferrimagnetic states. 
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applications, namely hyperthermia, high values of Ms and, more importantly, low values of Hc 
are required, as will be the case of superparamagnetism, where the coercivity is null. 
Hyperthermia is a type of cancer treatment in which localized body tissue is exposed to 
high temperatures. At temperatures higher than 40oC the natural enzymatic processes that keep 
cells alive start to wane, rendering them more susceptible to the effect of radiation or 
chemotherapy while inducing apoptosis. At even higher temperatures (circa 45oC) human cells 
stop working all-together and die (necrosis) in a process known as thermoablation [123]. 
Magnetic nanoparticles have the ability to dissipate heat when subjected to an 
alternating magnetic field via magnetic losses, which can be distinguished into three different 
mechanisms – hysteresis, Néel and Brown relaxations. There are also other mechanisms: the 
magnetic loss by friction in viscous suspension and Foucault currents in metallic materials. 
However, both shall be omitted since they mainly affect larger particles. 
Hysteresis losses (Figure 9.C) are a result of the uneven magnetization of the material 
during sequential magnetization cycles and may be derived from the integration of the 
hysteresis loops, representing the energy dissipated per cycle. They are the predominant loss 
mechanism in ferrimagnetic nanoparticles [124] and are inexistent in superparamagnetic 
materials, due to the obvious absence of hysteresis loops. 
 
  
Figure 8. Illustrative magnetic field dependencies of different materials’ magnetization during several magnetization 
cycles. Diamagnetism in green, paramagnetism in orange, superparamagnetism in blue and ferromagnetism, with its 
characteristic hysteresis loop, in yellow. 
 
In smaller nanoparticles, the heat dissipation is mainly caused by a delay in the 
relaxation of the magnetic moment. This moment behaves according to a uniaxial anisotropy, 
which means it only has two stable antiparallel orientations, both separated by an energy 
barrier. Therefore, two mechanisms are possible: either the magnetic moment manages to 
surpass the anisotropy barrier and shift while the particle remains fixed (Figure 9.A) or it fails 
and the particle rotates to compensate (Figure 9.B), causing energy dissipation by friction. 
Evidence shows that the first, Néel relaxation, holds a higher influence on superparamagnetic 
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nanoparticles [125, 126], while the second, Brown relaxation, is heavily influenced by the 
surrounding fluid’s viscosity [124]. Additionally, the heating rate is very dependent on particle 
size, while being maximized by a low polydispersity [126, 127]. 
Besides having a higher heating efficiency in comparison to larger multi-domain 
magnetic materials [128], superparamagnetic nanoparticles have many characteristics that 
make them ideal for a therapeutic approach. With the lack of a hysteresis loop, 
superparamagnetic materials do not retain magnetization once the external magnetic field is 
removed, thus avoiding particle agglomeration and complications thereof [129]. Despite 
extensive cell viability assays performed in regards to the cytotoxicity of superparamagnetic iron 
oxide nanoparticles (SPIONs), no considerable effect has been found at concentrations where 
other materials do exhibit it [130, 131]. 
 
SPIONs synthesis 
In past years, multiple synthetic approaches have been taken in order to obtain the 
perfect iron oxide nanoparticle. One of the earliest, and still much in use, was reported by 
Massart in 1981 [132], which he called co-precipitation. It consists in the addition of a base to 
an aqueous solution of ferrous (Fe2+) and ferric (Fe3+) ions in a 1:2 stoichiometric ratio under an 
oxygen free environment, preventing further oxidation, resulting in a black precipitate of less 
than 20 nanometers magnetite particles. Albeit this method offers an ease of controlling the 
nanoparticle’s size by adjusting the pH, reaction temperature, stoichiometric ratio and iron 
precursors, such ease is severely limited [133]. Additionally, without further surface 
modification, the nanoparticles are prone to be oxidized into γ-Fe3O4 [134]. To circumvent these 
limitations, other methods were elaborated, such as microemulsion (water in oil) [135, 136], 
limiting the crystal growth to the inside of micelles, hydrothermal [137, 138] and solvothermal 
decomposition [139, 140], disassembling large iron-containing molecules in aqueous and 
organic solvents, respectively, and the sonochemical method [141, 142], utilizing acoustic 
cavitation to create extreme heat and pressure localized conditions. However, each of these 
methodologies is accompanied by their own disadvantages, such as a difficult scale-up or the 
use of highly toxic solutions. As if to keep up with technology advancements, some variants of 
Figure 9. Illustrative representation of the three heat generating mechanisms by magnetic losses: Néel relaxation 
(A); Brown relaxation (B); and hysteresis (C). 
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the previous methods were adapted to take advantage of microwaves [143-145]. This type of 
radiation allows for a much faster and uniform heating, which consequently leads to quick, 
reproducible and efficient reactions [146]. 
During this work, due to a lack of experimentation in the field, multiple methods and 
optimizations in regards to SPION synthesis had to be employed. Choices were focused on co-
precipitation techniques, since these required no organic solvents and, theoretically, resulted in 
a large yield of smaller than 20 nanometers magnetic iron oxide nanoparticles. 
The iron-based powders were attained through Sigma-Aldrich and the ammonium 
hydroxide 25% solution was purchased from Merck with no extra purification step conducted. 
All water utilized was double-deionized with a conductivity inferior to 0.1 μS.cm-1. 
  
Conventional co-precipitation method 
The synthetic process utilized was based on the one described by Mahdavi et al, with 
some slight modifications [147]. 
In a typical procedure, ferric chloride hexahydrate (FeCl3 · 6H2O) and ferrous chloride 
tetrahydrate (FeCl2 · 4H2O), in a 2:1 molar ratio, were dissolved in 150 mL of double distilled 
water inside a three-necked closed flask, under a constant flow of nitrogen and vigorous 
magnetic stirring. After heating to 100oC, 20 mL of ammonium hydroxide (25%) was quickly 
added, turning the solution black. 30 minutes later, 3 mL of oleic acid was injected dropwise. 
The solution was then left stirring for one hour. Finally, the black precipitate was collected by 
magnetic separation with a strong permanent magnet and washed several times with double 
distilled water. 
 
Microwave-assisted co-precipitation method 
 The microwave synthesis was carried out in a Discover® SP microwave system, 
automated by Explorer-12 software, using 25 mL glass vessels with Teflon caps, all purchased 
from CEM Corporation. The reaction temperature was controlled by built-in sensors, allowing 
the wattage to increase or decrease as needed, with a 300 W maximum. Pressure was also left 
unregulated, allowing the vessels to self-vent as needed, with a 200 psi maximum. 
 The optimized procedure was conducted as followed. FeCl2 · 4H2O and FeCl3 · 6H2O were 
dissolved in 20 mL of double distilled water in a vessel under vigorous magnetic stirring. The 
stoichiometric ratio used was 1:1.8 to account for the probable oxidation of Fe2+ to Fe3+ and the 
total iron concentration was chosen as 0.07 molar, due to it being inside the optimum range. 3 
mL of 25% ammonium hydroxide was then rapidly added and the vessel removed from the 
stirring. After the precipitate settled, the vessel was placed inside the microwave system and 
the temperature set to 100oC, under maximum stirring, during 10 minutes. After the elapsed 
time, pressured nitrogen gas was injected into the system to quickly lower the temperature until 
70oC to stop the reaction. Lastly, the black precipitate was collected with a strong permanent 
magnet, washed 2 times and suspended in 25 mL of double distilled water. The nanoparticles 
were then stored in a 50 mL Falcon® at room temperature. 
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Characterization techniques 
Transmission Electron Microscopy – TEM 
TEM systems utilize a higher energy electron beam than SEM techniques, which, 
consequently, manages to interact with a sample at higher depths and achieve better resolution 
[148]. 
 The SPION images were obtained from a JEM-1400Plus Transmission Electron 
Microscope in Instituto de Biologia Molecular e Celular (IBMC). Uranyl acetate (1%) was used as 
contrast agent. 
 
X-ray Powder Diffraction – XRD 
When x-ray waves are emitted into a crystalline solid they are absorbed by the atoms in 
the lattice, which then re-emit electromagnetic waves of the same frequency. The angle upon 
which the x-ray waves approach the atom plane will cause the emitted waves to undergo either 
a constructive or destructive interference, originating a maximum intensity when the 
wavelength is an integer multiple of the distance between two atoms. 
A diffraction pattern can therefore be assembled by registering the emitted wave’s 
intensity as a function of the incident angle. In it, the peaks’ positions depend on the periodicity 
of the structure (i.e. the dimensions of the unit cell), whereas the peaks’ relative intensities 
relate to the distribution of scattering matter (i.e. the atoms or molecules) within the unit cell, 
which, in the case of XRD, is the electron density. Such relations equate into a unique diffraction 
pattern for every material, which allows their identification by a comparison with known 
patterns stored in databases [149, 150]. 
 The powder diffractometer utilized during this work was a Rikagu Smartlab (9KW) from 
the Institute of Material Physics of University of Porto. 
 
Superconducting Quantum Interference Device – SQUID 
SQUIDs are a type of extremely sensitive magnetometer which can measure magnetic 
fields as low as 10-14 T, due to a component called Josephson junction, an electronic circuit very 
sensitive to magnetic fluctuations. Since these circuits need to operate at near zero K 
temperatures, SQUIDs are equipped with a liquid helium refrigeration system [151]. 
For the purpose of this work, the magnetometer was utilized to measure the material’s 
magnetic response as a function of the applied magnetic field to determine the magnetic 
saturation, coercivity and residual magnetization and as a function of temperature in both zero 
field cooled and field cooled techniques to ascertain the blocking temperature and degree of 
superparamagnetism. 
All measures were taken in a Quantum Design superconducting quantum interface 
device (SQUID) from the Institute of Material Physics of University of Porto. 
  
Results and discussion 
 The initial particles, synthesized by the conventional co-precipitation method, were 
analyzed by DLS, which determined their size to be circa 1 micrometer. Since the objective of 
this work requires magnetic particles of smaller diameters, an exhaustive optimization process 
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was performed and, inclusively, the synthesis method was changed. All the nanoparticles were 
synthesized by the microwave-assisted method, which proved to be more reliable and extremely 
faster. 
 During the course of all the experimental process, all the synthesized nanoparticles 
remained stable in the solution, showing no signs of aggregation or precipitation. 
 As a somewhat crude method to evaluate the SPIONs’ magnetic capabilities, a small 
permanent magnet was put into contact with the vial during a 5 second timeframe. This method 
was applied to all synthesized magnetic nanoparticles, as it represents a very quick, reliable and 
inexpensive procedure to ascertain a prognosis of the nanoparticle’s magnetic character. 
 In Figure 10 it is possible to denote the three different stages of such method during the 
referenced timeframe. Before the approach of the permanent magnet, the solution is a 
completely dispersed, opaque, black suspension. However, at the moment of magnetic 
exposure, the nanoparticles are met with a near-instant attraction, resulting in a progressive 
purification of the aqueous medium until, proceeding an elapsed time of circa 5 seconds, all the 
SPIONs concentrate, as close as they can to the permanent magnet, in a magnetic slurry. 
Afterwards, a simple vigorous agitation returns the solution to its prime condition. 
 
 
Figure 10. SPION solution response to a small permanent magnet. From left to right: the baseline suspension state 
prior to magnetic exposure; 1 second after the magnet’s placement; and 5 seconds of magnetic influence. 
 
The magnetic nanoparticles’ morphological analysis was executed by TEM imaging, 
which indicated sizes ranging from 5 to 15 nanometers and spherical shape (Figure 11). 
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Figure 11. TEM image of microwave-assisted synthesized SPIONs with TEM-assisted size measurements. 
 
The structural characterization was made by XRD. Figure 12 presents the diffraction 
pattern of the synthesized nanoparticles in comparison to that of pure magnetite, which was 
obtained from the RRUFF database (RRUFF ID: R061111.9). The peaks’ juxtaposition indicates a 
high crystallinity of the SPIONs and the likely presence of a single magnetic phase. It is however 
possible the existence of a small amount of maghemite undiscernible by the XRD pattern, since 
its diffraction peaks differ from those of magnetite for only a few degrees leading to overlaps 
and consequent occlusions [152]. 
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Figure 12. XRD diffraction patterns of pure magnetite (top) and the synthesized SPIONs (bottom). 
 
The nanoparticle’s magnetic characterization was conducted through SQUID 
measurements. According to the magnetization measurements as a function of the applied 
magnetic field (Figure 13), the magnetite nanoparticles have a remarkable magnetic coercivity 
of 6 Oe at room temperature. However, with decreasing temperature the coercivity increases, 
reaching 180 Oe at 10 K. Since 10 K is sure to be below the blocking temperature, the increase 
of coercivity can be explained by the blocked state of the nanoparticles’ magnetic domains, in 
which the fluctuation of magnetization is severely impaired and confers the “magnetic memory” 
commonly associated with ferromagnetic materials, which means the formulation contains a 
few multi-domain particles. 
 
 
Figure 13. M(H) SQUID measurements of the synthesized SPIONs, at 300K and 10K, and a centered, zoomed version 
of each. 
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To gather further information on the SPIONs blocking temperature, zero-field-cooled 
(ZFC) and field- cooled (FC) measurements were conducted (Figure 14). 
 
 
Figure 14. Zero-Field-Cooled and Field-Cooled measurements of the synthesized SPIONs. 
  
The SPION sample was first cooled to 5 K under no magnetic field and then slowly heated 
to 300 K under the effect of a 50 Oe field. Afterwards, still under the applied magnetic field, the 
sample suffered another temperature cycle. The magnetic measurements were all made during 
the heating phase. The FC curve presents a well-defined plateau, most likely unveiling the 
presence of strong dipolar interactions between the particles. These interactions also explain 
the ZFC curve’s quasi-linear behavior, having no pronounced inflections, which precludes the 
determination of the blocking temperature, since the interactions cause it to shift to higher 
temperatures [153]. However, there is a slight change in the ZFC curve’s increase rate at 25 and 
150 K, which represents the unblocking of some of the smaller nanoparticles in the sample. 
Therefore, the data acquired confirms the successful synthesis of somewhat 
polydisperse superparamagnetic iron oxide nanoparticles, with strong interparticle dipolar 
interactions. 
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Chapter 4 
 
SPION-Paclitaxel-loaded Nanostructured Lipid Carriers 
 
Introduction 
 Aristotle once said: “The whole is greater than the sum of its parts”. Little did he know 
how this synergistic concept could be applied in nanotechnology. 
 As described in the previous chapters, superparamagnetic iron oxide nanoparticles have 
received much attention by the nanomedicine scientific community. Recently, an idea has 
surfaced to combine both the magnetic and lipid/polymeric nanoparticles to create a hybrid 
containing the advantages of both worlds.  
 Lipid-based and polymeric nanoparticles are extensively used as drug vehicles due to 
their ease of chemical and structural modulation to achieve a controlled in vivo circulation and 
release of drugs (improved bioavailability and half-life), and a tissue-selective targeting, which 
results in a minor biodistribution, in a reduced quantity of the active compound required and, 
therefore, in reduced possible side effects. Moreover, the nanoparticles act as a barrier to drug 
release, effectively controlling its solubility and diffusivity [154]. With the addition of magnetic 
nanoparticles to the formulation, these advantages widen to encompass hyperthermic 
capabilities. Additionally, due to this unique combination, the increase of heat can not only 
promote cell death but also the nanoparticle’s enhanced permeability or even total burst release 
by affecting its matrix’s fluidity (Figure 15). However, despite all of the promising advantages, 
this field has not received much attention. 
Müller et al demonstrated, in 1996, the possibilities arising from SPION encapsulated 
polymeric and solid lipid nanoparticles [155]. Since then, most of the focus was directed to 
magnetoliposomes [7, 156-158]. There have also been reports of successful encapsulation of 
magnetite particles in SLNs [159-161]. However, at the time of writing, the author was unable 
to locate reports of SPION-loaded nanostructured lipid carriers and their applications. 
 
 
Figure 15. Illustrative representation of hyperthermia-aided release in a lipid nanoparticle. 
27 
 
 
SPION-loaded NLC synthesis 
 The synthesis protocol (Figure 16) followed was a slight adaptation of the one described 
in Chapter 2, taking into account the addition of magnetic nanoparticles. 
 
 
Figure 16. Representative diagram of the SPION-NLC synthesis process by an ultrasonication technique. From left to 
right: addition of water and SPIONS to melted lipid, surfactant and drug, sonication and final product. 
 
 In a typical procedure, 70% (w/w) of Gelucire® 43/01, 6% (w/w) of Compritol® 888 ATO, 
10% (w/w) of Miglyol® 812, 12% (w/w) of Tween® 80 and 2% (w/w) of Paclitaxel were weighted 
and placed in a glass tube. The tube was then submerged in a water bath at 75oC until all lipids 
had melted and magnetically stirred to suspend the drug. Afterwards, 16 mL of double distilled 
water, pre-heated at 75oC and 1 mL of room temperature SPION solution (as prepared by the 
method described in Chapter 3) were added, obtaining an opaque, brown suspension, which 
was placed under the probe-sonicator at 104 W of potency during 10 minutes. The resulting 
brown nanoemulsion was stored in a sealed glass vial and left to cool at room temperature. 
 
Box-Behnken experimental design 
 In statistics, Box-Behnken are a type of experimental designs for surface response 
methodology. Their prime usefulness lies on the clever positioning of the process space 
boundaries, leading to fewer design points and, therefore, less expensive and time consuming 
[162]. Numerous reports have confirmed the eligibility of this experimental design for 
nanopharmaceutics optimization [103, 163-166]. 
 The Box-Behnken design utilized for the purpose of optimizing the SPION-, Paclitaxel-
loaded NLCs was trifactorial (Figure 17) with three responses. The factors in use were the 
Gelucire® 43/01 to Miglyol® 812 ratio, amount of Paclitaxel and duration of sonication, while 
the responses measured were the nanoparticles’ size, polydispersity and encapsulation 
efficiency. All factors consisted of a three level combination of high, low and midpoint. 
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Figure 17. Design geometry for the Box-Behnken 3-factor design.  
 
Release studies’ methodology 
 One of the most important characteristics of a newly engineered drug-loaded 
nanoparticle is its release kinetics. Numerous methods have been reported to assess such 
kinetics, among which the most common were ultracentrifugation, centrifugal ultrafiltration and 
pressure ultrafiltration. Potential issues arising from these techniques include a deficient 
physical separation, causing the presence of nanoparticles in the measured sample and leading 
to significant measurement errors, particularly early in the release timescale [167]. Nowadays, 
the dynamic dialysis method is almost exclusively utilized for this kinetic assessment since it 
overcomes the previously described issues by avoiding the frequent separation processes [168]. 
 The dialysis device utilized was a Float-a-Lyzer® G2, marketed by Spectrum Laboratories, 
with 1 mL of working volume and a molecular weight cutoff of 3.5 to 5 kDa. 
For the release kinetics study, 1 mL of the synthesized NLC formulation was placed inside 
a previously moist dialysis tube. The surrounding medium was a Phosphate Buffer Solution 
containing sodium salicylate at 0.5 M concentration and pH-corrected with hydrochloric acid as 
needed. The assay was conducted at 37oC and at the pH levels of 7.4 and 6.3 to simulate 
physiological and neoplastic conditions, respectively. Samples were collected hourly during 8 
hours for three consecutive days and analyzed with a spectrophotometer at 200-400 nm. 
 
Results and discussion 
 As previously described, a Box-Behnken design was elaborated for the purpose of 
nanoparticle optimization. This design implicated the synthesis of 15 different NLC formulations 
and their individual characterization. In Table 4 are depicted the variables modified between 
these formulations and Table 5 shows their physicochemical characterization. The 
nanoparticle’s size utilized herein after is a weighted average of the biggest population (in 
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number) and not the mean diameter calculated by the software, since the NLC suspension 
contains a few large outlier nanoparticles which contribute to an erroneous computational 
analysis. 
 
Table 4. Synthesis variables for the trifactorial Box-Behnken experimental design. 
Formulation 
# 
Solid to liquid lipid 
ratio 
Amount of loaded drug 
(mg) 
Sonication time 
(min) 
1 5 5 10 
2 7 5 10 
3 5 15 10 
4 7 15 10 
5 5 10 5 
6 7 10 5 
7 5 10 15 
8 7 10 15 
9 6 5 5 
10 6 15 5 
11 6 5 15 
12 6 15 15 
13 6 10 10 
14 6 10 10 
15 6 10 10 
 
 
Table 5. Physicochemical characteristics of the synthesized NLCs. 
Formulation 
# 
Nanoparticle size 
(nm) 
Polydispersity Index 
(adimensional) 
Encapsulation 
efficiency (%) 
1 54.0 0.152 68.0 
2 172.3 0.133 70.3 
3 110.8 0.181 90.3 
4 104.9 0.151 79.4 
5 131.1 0.160 82.8 
6 82.7 0.185 79.4 
7 57.6 0.145 77.9 
8 94.9 0.165 81.1 
9 126.5 0.166 64.3 
10 104.9 0.186 87.2 
11 144.9 0.150 66.4 
12 132.1 0.168 76.4 
13 128.8 0.181 81.0 
14 126.8 0.162 77.1 
15 129.23 0.149 80.2 
 
 Box-Behnken design softwares illustrate the dependencies of measured responses to 
the factorial variables by tridimensional graphics. Three of the obtained graphics are depicted 
in Figure 18. 
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Figure 18. Graphical representation of three of the dependencies determined by the Box-Behnken design. Top left: 
Encapsulation efficiency according to amount of drug (y axis) and solid to liquid lipid ratio (x axis); Top right: Particle 
diameter according to time (y axis) and solid to liquid lipid ratio (x axis); Bottom: Particle diameter according to 
amount of drug (y axis) and solid to liquid lipid ratio (x axis). 
 
According to the calculations accomplished through the Box-Behnken software, all the 
synthesis parameters had a significant influence on the formulations’ measured 
physicochemical characteristics.  
The formulation chosen to conduct the remainder of this work was formulation 8, due 
to its acceptable compromise between polydispersity and encapsulation efficiency, while 
retaining the ideal size below 200 nanometers. 
During the weeks encompassing the experimental procedures, the NLCs showed no 
signs of precipitation or degradation, indicating a positive stability. Additionally, the 
suspension’s light brown color and lack of black precipitate was evidence of successful SPION 
encapsulation. 
Figure 19 depicts a simple visual comparison regarding the presence of magnetic 
nanoparticles in 5 weeks old formulations. First and foremost, the highly evident alteration is a 
change in the suspension’s color from white (Figure 19.B), in SPIONs’ absence, to a light brown 
(Figure 19.A), in the complete formulation. Additionally, a very interesting aspect of the SPIONs’ 
encapsulation is their ability to drive the NLCs upon a magnetic field exposure as evidenced by 
Figure 19.C. 
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Figure 19. Comparison between the NLC-Paclitaxel-loaded (A) and Paclitaxel-loaded formulations (B) and the 
magnetic field influence on the first (C). 
 
Cryo-SEM was used to further analyze the nanoparticle’s morphology and evaluate their 
comparison to the previously synthesized simpler NLCs. 
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Figure 20. Cryo-SEM images of placebo NLCs (A), Paclitaxel-loaded NLCs (B), SPION-loaded NLCs (C) and SPION-
Paclitaxel-loaded NLCs (D). 
  
 Through the images provided by the electronic microscope it is possible to notice a 
decrease in diameter and polydispersity as a consequence of SPION encapsulation (Figure 20.A 
to Figure 20.C). Additionally, there is no noticeable change between placebo and drug 
encapsulating NLCs (Figure 20.A to Figure 20.B and Figure 20.C to Figure 20.D). As expected, all 
nanoparticles showed to be quite labile even while frozen. 
 To further ascertain SPION successful encapsulation, XRD was utilized and the resultant 
spectrum of the NLCs was compared to that of pure magnetite (Figure 21). All of the 
characteristic magnetite peaks are present, with the exception of the first at circa 18 degrees, 
which is absent due to a wide peak of, presumably, Gelucire® 43/01, indicating the presence of 
the SPIONs in the NLCs’ interior. 
 The magnetic characterization proceeded similarly to the one described for free SPIONs. 
Additionally in a similar fashion, the coercivity had a value of 6 Oe at 300 K, indicating a 
superparamagnetic behavior, and 288 Oe at 10 K, due to the previously elucidated reason 
(Figure 22). However, at all temperatures, the magnetization suffered a steep decline after 
reaching saturation. The most likely explanation for such is based on the diamagnetic properties 
of the NLCs’ lipidic matrix. With SPION-Paclitaxel-loaded NLCs, there are five magnetic states in 
balance exerting a force in the outer field: the SPION’s superparamagnetism and diamagnetism, 
the Paclitaxel diamagnetism, the NLC’s lipids’ diamagnetism and the sample support’s 
diamagnetism. At low applied fields, the superparamagnetism effect is prevalent over all the 
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other forces combined. However, after reaching saturation, its effect can no longer increase and 
the diamagnetic effects take hold. It is possible to correct the values by eliminating the influence 
of this diamagnetic effect (Figure 23). 
 
 
Figure 21. XRD diffraction patterns of pure magnetite (top) and the synthesized SPION-Paclitaxel-loaded NLCs 
(bottom). 
 
 
Figure 22. M(H) SQUID measurements of the synthesized SPION-Paclitaxel-loaded NLCs at 300 K and 10 K, a centered, 
zoomed version of each (top). 
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Figure 23. Corrected values of M(H) SQUID measurements of SPION-Paclitaxel loaded NLCs at 10 K (left) and 300 K 
(right). 
 
 
Figure 24. Zero-Field-Cooled and Field-Cooled measurements of a synthesized SPION-loaded NLC placebo. 
 
To possibilitate the determination of the SPION’s blocking temperature, a SPION-loaded 
NLC placebo was made, with the aim of decreasing the strong interparticle dipolar interactions 
and eliminate their influence in the zero-field-cooled and field-cooled measurements (Figure 
24). This time, the FC curve showed a characteristic elevation, correlated with the successful 
inhibition of such interactions and the consequent temperature shift. Therefore, it was possible 
to determine the point of curve juxtaposition present at 300 K, which is associated with the 
irreversible temperature, the highest blocking temperature of the ensemble [169]. The mean 
blocking temperature, since the formulation was somewhat polydisperse, was determined 
through the temperature derivative of the difference between FC and ZFC magnetization curves, 
to which its maxima corresponds [152]. The calculated mean Tb was, surprisingly, 106.4 K. 
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 An in vitro paclitaxel release study was conducted in a simulated physiological and 
neoplastic environment condition, as pH is regarded, through a dynamic dialysis method. As can 
be observed in Figure 25, the release from nanoparticles in the more acidic medium occurs 
always at a higher degree than in the physiological condition. It is interesting to consider the two 
distinct regimes denoted by both release profiles, a particularity from this formulation unlike 
the common drug-encapsulating nanoparticles, which usually present both regimes in the 
inverse order. The most likely reason for such is the lack of paclitaxel bound to the particle’s 
surface, wherein most nanoparticles have a fraction of their drug. This surface-bound drug is 
commonly released in a burst-like fashion, to which the encapsulated drug follows in a 
controlled and encompassed manner. In this case, the drug-free surface avoids the initial violent 
release and is demarked by a more stable one followed by a, henceforth denominated, 
controlled burst.  
 The first regime lasts 29 hours, during which only 4.7% and 1.6% of cumulative paclitaxel 
amount was released, in neoplastic and physiological simulated conditions, respectively. This 
sustained release resulted, mainly, from the rearrangement of the particles’ structure due to 
the rise of temperature. 
 The second regime takes hold at the 30th hour and is prominent until the end of the 
experiment, 68 hours and 20 minutes after the sample is placed in the sink. During this time, a 
cumulative amount of 30.6% and 25% of paclitaxel was released at pH 6.3 and 7.4, respectively. 
The controlled burst release is a result of the continuous weakening and progressive instability 
of the nanoparticle’s physical structure, as it augments its lability over time due to the 
temperature’s close proximity to its melting point, and thereby releases the entrapped drug 
through a diffusion mediated process. 
 Relating both conditions to one another, it is possible to ascertain a more pronounced 
release within the simulated neoplastic environment in absolute value. Akin to such, its rate of 
increase is slightly higher during both of the regimes. 
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Figure 25. In vitro paclitaxel release profile from SPION-loaded nanostructured lipid carriers. 
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Chapter 5 
 
Final remarks 
 
 The Paclitaxel-loaded NLC formulation was optimized as intended, presenting a size of 
117.83 nm, lower than the 200 nm limit, a polydispersity index of 0.113, indicating 
monodispersity, and a ζ-potential of -29.2 mV, suggesting a high stability. The encapsulation 
efficiency achieved was higher than 99%, a value greater than other author had previously 
reported. The microscopy images were concurrent with the previously measured size and 
polydispersity index and evidenced a spherical shape. 
 During the second experimental section, the classical co-precipitation methodology for 
SPION synthesis was found to be unreliable and lengthy in relation to the more modern 
microwave-assisted one. The sizing measurements were limited to microscopy imaging since a 
standard DLS is incapable of identifying such small nanoparticles. The images showed a slightly 
polydisperse combination of SPIONs averaging 10 nm, indicating a paramagnetic state in 
concurrence to the initial post-synthesis test with a permanent magnet. The XRD diffraction 
patterns evidenced a high crystallinity, albeit not disregarding the possible presence of a 
maghemite phase, representing a good magnetic and structural purity. Magnetization 
measurements were also conducted, resulting in a virtually null magnetic coercivity at room 
temperature, evidence of a purely superparamagnetic behavior. The ZFC/FC assays indicated 
the presence of strong interparticle dipole interactions, due to a horizontal FC curve and pseudo-
straight ZFC curve, and the already established slight polydispersity through the changes in the 
ZFC curve’s increase rate at 25 K and 150 K. 
 Lastly, the optimized Paclitaxel-SPION-loaded NLC formulation was successfully 
determined through a Box-Behnken design procedure. The resulting formulation was 
synthesized with a ratio of solid to liquid lipid of 7, 10 mg of Paclitaxel and 15 minutes of 
sonication, and resulted in a 94.88 nm average nanoparticle with 0.165 polydispersity index and 
an encapsulation efficiency of 81.14%. The ζ-potential was found to be unaffected by the SPION 
presence. The images provided by cryomicroscopy denoted a decrease in size and polydispersity 
as a consequence of the magnetic nanoparticles encapsulation, while no such change is 
noticeable between the placebo and Paclitaxel-loaded lipid nanoparticles. Additionally, the 
results were in agreement with the previously measured results by the DLS and evidenced a 
sphere-like shape. The XRD measured diffraction patterns contained most of the same peaks as 
the ones obtained from the free SPIONs, with the exception of an obscuration at 18 degrees, 
most likely caused by the high content of Gelucire® 43/01. In a similar fashion, the magnetization 
measurements determined a purely superparamagnetic behavior at room temperature 
resulting from a near zero magnetic coercivity. However, they also presented a slight caveat 
since, after reaching magnetic saturation, the superparamagnetism of the SPIONs is lost amidst 
the diamagnetic properties of all the other formulation components. Lastly, the release study 
indicated an uncommon drug release profile. During the first 29 hours, the sample at pH 6.3 
released almost 3-fold the amount of paclitaxel that the sample at pH 7.4 did (4.7% and 1.6%), 
both following a controlled regime. Afterwards, both samples entered a controlled burst regime, 
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exponentially increasing the quantity of released drug, amounting to 30.6% and 25% for 
neoplastic and physiological simulated environment, respectively. These values indicate that the 
nanoparticle is more prone to release paclitaxel near solid tumors than it is at a healthy tissue. 
Overall, this scientific pilgrimage resulted in accomplishment in all three fronts of work. 
The resulting final formulation is, undoubtedly, a promising candidate for the template of 
tomorrow’s antineoplastic therapies by combining the diminished noxious effects and 
controlled release property of regular drug-loaded nanoparticle to the hyperthermic capabilities 
of magnetic nanoparticles, all while creating the additional effect of a burst drug release on-
demand. 
 
Future work 
 
An attempt into science’s progress is never finished, as there is always something else 
to be done. 
Specific to this thesis, the logical continuation would be calorimetric assays to precisely 
and accurately determine the nanoparticle’s heating rate, since their superparamagnetic 
behavior indicates solely that they can heat, not how steeply nor how efficiently. Allied to such, 
it would be advantageous to verify the relationship between the heating drug releasing 
properties, such as in a heat-variating release study. Additionally, a more defined stability study 
is in order, since a time dependent variation (or lack thereof) of nanoparticle diameter and/or ζ-
potential represents a more definitive proof than the lack of drug and SPION precipitate in 
months old formulations. Lastly, cell viability assays need to be conducted in different healthy 
and neoplastic cell lines under different magnetic field exposures to identify the nanoparticles’ 
cytotoxicity properties in such conditions. 
As a final approach, departing from an academic view to a more commercially oriented 
one, the formulation should also be trialed in vivo in animal models and, ultimately, humans. 
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